Stockreport

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL [Yahoo! Finance]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring a leadin [Read more]